Open AccessCase report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
Author(s) -
Wang Hongmei
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12506
Subject(s) - apatinib , medicine , mesylate , adenoid cystic carcinoma , radiation therapy , rare disease , chemotherapy , carcinoma , radiology , surgery , pathology , disease , chemistry , organic chemistry
A 57‐year‐old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantly relieved. Treatment with apatinib mesylate represents a novel method of treatment for tracheal adenoid cystic carcinoma.